United States

Photocure ASA (PHO.OL)

PHO.OL on Oslo Stock Exchange

25 Oct 2016
Change (% chg)

kr-0.60 (-1.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PHO.OL


Photocure ASA is a Norway-based company active in the pharmaceutical industry. It operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development... (more)


Beta: 0.43
Market Cap(Mil.): kr816.57
Shares Outstanding(Mil.): 21.55
Dividend: --
Yield (%): --


  PHO.OL Industry Sector
P/E (TTM): 270.69 36.18 36.06
EPS (TTM): 0.14 -- --
ROI: 1.30 14.41 13.90
ROE: 1.32 15.18 14.84

BRIEF-Photocure: Hexvix marketing authorization approval in Australia

* Says partner, Juno Pharmaceuticals Pty Ltd, has received marketing authorization approval (MAA) for Hexvix in Australia

Aug 24 2016

BRIEF-Photocure Q2 operating loss widens to NOK 4.4 million

* Q2 sales revenue 34.2 million Norwegian crowns versus 28.9 million crowns year ago

Aug 23 2016

BRIEF-Photocure: Cysview granted FDA approval of new prefilled syringe

* U.S. Food & Drug Administration has granted approval for an improved packaging for Cysview Source text for Eikon:

Aug 11 2016

BRIEF-Photocure: Share capital increase in connection with exercise of options

* Says has resolved share capital increase in connection with exercise of options

May 23 2016

BRIEF-Photocure Q1 operating loss narrows to NOK 4.9 mln

* Q1 sales revenue 33.5 million Norwegian crowns ($4.07 million) versus 28.4 million crowns year ago

May 10 2016

BRIEF-Photocure presents positive clinical data on BLC with Cysview/Hexvix

* Announces positive clinical data on Blue Light Cystoscopy (BLC) with Cysview/Hexvix

May 09 2016

Earnings vs. Estimates